Cell Signaling Technology

ZHX2 Antibody

#20937 · $317

87
Citing papers
4.2k
Combined citations
Supplier page Find this product

Research areas

Lung Cancer Treatments and Mutations35PI3K/AKT/mTOR signaling in cancer22HER2/EGFR in Cancer Research12Cancer-related Molecular Pathways8Liver physiology and pathology8Cancer Mechanisms and Therapy7Colorectal Cancer Treatments and Studies7Lung Cancer Research Studies6

Papers citing this product

1
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Nature Communications·2016·657 cit.·DOI
2
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor <i>BRAF</i> gene mutations but lack mutations in <i>KRAS, NRAS,</i> or <i>MEK1</i>
Proceedings of the National Academy of Sciences·2012·436 cit.·DOI
3
A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop
Oncogenesis·2013·256 cit.·DOI
4
Met Activation in Non-Small Cell Lung Cancer Is Associated with de Novo Resistance to EGFR Inhibitors and the Development of Brain Metastasis
American Journal Of Pathology·2010·184 cit.·DOI
5
Activating MET kinase rearrangements in melanoma and Spitz tumours
Nature Communications·2015·161 cit.·DOI
6
The adhesion G protein-coupled receptor GPR56 is a cell-autonomous regulator of oligodendrocyte development
Nature Communications·2015·142 cit.·DOI
7
Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target
Oncology Reports·2011·135 cit.·DOI
8
N-Cadherin Expression Is Associated with Acquisition of EMT Phenotype and with Enhanced Invasion in Erlotinib-Resistant Lung Cancer Cell Lines
PLoS ONE·2013·130 cit.·DOI
9
A Perspective on Challenges and Issues in Biomarker Development and Drug and Biomarker Codevelopment
JNCI Journal of the National Cancer Institute·2009·127 cit.·DOI
10
Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
British Journal of Cancer·2009·91 cit.·DOI

Similar products

ProductVendorPricePapers
ZHX2 (E5H5G) Rabbit Monoclonal AntibodyRabbitCell Signaling Technology$1617
ZHX2 Antibody — Evidence — PubIndex